Hemosol receives clearance to begin study of HEMOLINK.
D000740:Anemia / Q000139:chemically induced / Q000188:drug therapy; D017322:Clinical Trials, Phase II as Topic / Q000331:legislation & jurisprudence / Q000379:methods; D017277:Drug Approval / Q000331:legislation & jurisprudence; D004345:Drug Industry / Q000331:legislation & jurisprudence*; D006454:Hemoglobins / Q000627:therapeutic use*; D006801:Humans; D011887:Raffinose / Q000031:analogs & derivatives / Q000627:therapeutic use*; D016037:Single-Blind Method; D014481:United States; D014486:United States Food and Drug Administration
D006454:Hemoglobins; C097124:O-raffinose cross-linked human hemoglobin; D011887:Raffinose